BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly’s Weight-Loss Drug Mounjaro Gains Traction in India Amid Rising Obesity and Diabetes
Eli Lilly’s Weight-Loss Drug Mounjaro Gains Traction in India Amid Rising Obesity and Diabetes
10
1
Eli Lilly's stock (LLY) surged as sales of its weight-loss drug Mounjaro soared in India, with 81,570 units sold for 239.4 million rupees ($2.76 million) by May. The drug saw a 60% sales jump between April and May, outpacing rival Novo Nordisk (NVO) in the lucrative Indian market.
India's growing affluence has brought a surge in obesity and diabetes, with 25% of adults aged 15-49 now overweight or obese. The International Diabetes Federation projects diabetes cases will rise to 124 million by 2045, creating a massive opportunity for Mounjaro's mass-market pricing to dominate treatment.
By:
Previous
Klarna CEO Bets on AI to Power Financial ’Super App’ Ambitions
Next
Alphabet’s Robotics AI Push Signals Emerging $100B Market Opportunity
